StemCells (STEM) PT Cut to $3 at Maxim Group

Go back to StemCells (STEM) PT Cut to $3 at Maxim Group

UPDATE: StemCells (STEM) Declines After Shares Resume Trading

December 23, 2015 8:10 AM UTC

(Updated - December 23, 2015 8:16 AM EST)

StemCells (NASDAQ: STEM) Declines After Shares Resume Trading

... More

StemCells (STEM) to Suspend Phase II Radiant Study in GA-AMD, Cut Workforce by 25%

December 23, 2015 8:07 AM UTC

StemCells, Inc. (NASDAQ: STEM) today announced a strategic realignment to fully focus the Companys resources on its proprietary HuCNS-SC® platform technology for the treatment of chronic spinal cord injury (SCI).

Evidence of efficacy from the Companys ongoing clinical trials in chronic SCI offers therapeutic promise to restore lost function previously considered unrecoverable. StemCells recently reported a pattern of improvements in both strength and motor function, six months post-transplant of its proprietary HuCNS-SC cells, in the first cohort of its Phase II Pathway Study in cervical spinal cord injury. These interim... More

StemCells (STEM) Halted, News Pending

December 23, 2015 8:01 AM UTC

StemCells (NASDAQ: STEM) Halted, News Pending

... More